Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson & Johnson Inc. JNJ

Johnson & Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

In the VARIPURE substudy of the SECURE trial, the company's VARIPULSE Platform for pulsed field ablation in atrial fibrillation showed 99.7% acute effectiveness, no strokes, and a 0.6% adverse event rate among 791 patients.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.